Home/Filings/4/0001567619-21-012643
4//SEC Filing

Abuse Deterrent Pharma, LLC 4

Accession 0001567619-21-012643

CIK 0000786947other

Filed

Jun 27, 8:00 PM ET

Accepted

Jun 28, 11:00 AM ET

Size

8.6 KB

Accession

0001567619-21-012643

Insider Transaction Report

Form 4
Period: 2021-06-09
Transactions
  • Conversion

    Convertible Promissory Note

    2021-06-096,877,5000 total
    Exercise: $0.16From: 2019-06-28Common Stock (42,984,375 underlying)
  • Conversion

    Common Stock

    2021-06-09$0.16/sh+42,984,375$6,877,50042,984,375 total
Holdings
  • Warrant to Purchase Common Stock

    Exercise: $0.53From: 2017-07-24Exp: 2022-07-23Common Stock (1,782,531 underlying)
    1,782,531
Footnotes (2)
  • [F1]The note bears interest at the rate of 7.5% per annum. On the conversion date, all principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock.
  • [F2]This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023.

Documents

1 file

Issuer

ACURA PHARMACEUTICALS, INC

CIK 0000786947

Entity typeother
IncorporatedKY

Related Parties

1
  • filerCIK 0001782327

Filing Metadata

Form type
4
Filed
Jun 27, 8:00 PM ET
Accepted
Jun 28, 11:00 AM ET
Size
8.6 KB